Who are Orisdx's investors?

Orisdx's investors include Angel Physicians Fund, HARPER COURT VENTURES.

How much funding has Orisdx raised?

Orisdx has disclosed $2.8M raised across 1 round.

Where is Orisdx headquartered?

Orisdx is headquartered in Chicago, US.

Orisdx

Chicago, US · Founded 2022 · Delaware corporation · 9 employees on LinkedIn · 2 known investors

Find your way into Orisdx

211 people in our graph share verified history with the Orisdx team — schools, employers, funds. One of them is your warm intro.

Dougunlockedknows Harald Steltzer · together at University of Wisconsin-Madison (overlapped)

knows the team · via Orisdx

×6knows the team · via Genzyme

knows the team · via U.S. Soccer Federation

knows the team · via Augustana College

knows the team · via University of Wisconsin-Madison

OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.

Biotech Digital Health Medical Devices

Founders & leadership

Harald Steltzer inChief Executive OfficerHarald Steltzer has spent over three decades in life sciences and healthcare entrepreneurship, with expertise in business strategy, market access, and corporate development across the healthcare industry.

Patrick Conniff inChief Operating & Financial OfficerHe previously worked across life sciences, consumer products, and nonprofit sectors on fundraising, partnerships, and business development, and earned his MBA from Booth School of Business.

Evgeny IzmchenkoNamed on SEC filing

Nishant AgrawalinCo-Founder

Investors · 2

Angel Physicians Fund

HARPER COURT VENTURESChicagovia Karthee Madasamy · inferred

Reported raises · per SEC filings

Form D private placements

$2.8M disclosed across 1 round · 2025

▶$2.8MraisedJul 2025 · 25 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Harald SteltzerExecutive Officer, Director
Evgeny IzmchenkoDirector
Patrick ConniffExecutive Officer
Nishant AgrawalDirector

Offering amount: $4M
Amount sold: $2.8M
First sale: May 2025
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Orisdx do?: OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.
Who are Orisdx's investors?: Orisdx's investors include Angel Physicians Fund, HARPER COURT VENTURES.
How much funding has Orisdx raised?: Orisdx has disclosed $2.8M raised across 1 round.
Where is Orisdx headquartered?: Orisdx is headquartered in Chicago, US.